Beneficial Effects of Coronary Venous Retroinfusion of Superoxide Dismutase and Catalase on Reperfusion Arrhythmias, Myocardial Function, and Infarct Size in Dogs

Hatori, Nobuo; Miyazaki, Akira; Tadokoro, Hiroyuki; Rydén, Lars; Moll, J; Rajagopalan, R.; Mc, Fishbein; Meerbaum, Samuel; Corday, Eliot; Jk, Drury

doi:10.1097/00005344-198909000-00007

Cited by 33 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presumably, high myocardial levels can explain why comparatively low doses of both MDL 74,270 and MDL 73,404 are required for myocardial salvage in conditions of reperfusion injury. This relative myocardial selectivity of the two compounds represents an advantage over other antioxidants, such as superoxide dismutase or catalase, which have to be introduced into the ischemic myocardium by coronary venous retroinfusion in order to achieve adequate concentrations (18). Cardiac selectivity is apparently not limited to quaternary ammonium compounds (28.30) but is a feature common to many quaternary substituted compounds (37)(38)(39)43).…”

Section: Chemistrymentioning

confidence: 99%

MDL 73,404: A Cardioselective Antioxidant that Protects Against Myocardial Reperfusion Injury

Petty¹

1992

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Section: Chemistrymentioning

confidence: 99%

MDL 73,404: A Cardioselective Antioxidant that Protects Against Myocardial Reperfusion Injury

Petty¹

1992

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…However, enzymatic elimination of reactive oxygen species by superoxide dismutase and catalase lacked in vivo efficacy in preclinical large animal models [9][10][11] although myocyte protection was achieved in vitro [12]. Alternatively, supplementation of physiological ROS scavengers such as GSH is an attractive option, since intracellular GSH levels decrease rapidly after ROS-exposure.…”

Section: Introductionmentioning

confidence: 99%

Selective retroinfusion of GSH and cariporide attenuates myocardial ischemia–reperfusion injury in a preclinical pig model

Kupatt

Hinkel

Horstkotte

et al. 2004

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…43 Favorable results in terms of preservation of regional myocardial function and reduction of infarct size were obtained after retrograde injection of recombinant tissue-type plasminogen activator, different calcium blockers, superoxide dismutase, catalase, and L-arginine. [43][44][45][46][47][48][49] However, despite these observations, the retrograde drug administration via the coronary venous system has not been introduced into clinical practice.In patients with chronic refractory ischemia, 2 treatment methods using a transvenous coronary approach were recently tested. The potential for percutaneous coronary artery bypass grafting in situ has been evaluated in animal models and different catheter-based techniques have been extensively tested.…”

mentioning

confidence: 99%

Trans-Coronary-Venous Interventions

Siminiak¹,

Lipiecki²

2008

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Abstract-The coronary venous system is routinely targeted during electrophysiological measurements or cardiac resynchronization therapy. However, several novel interventional techniques require coronary venous catheterization and visualization as well as transvenous delivery of devices and/or therapeutic agents. Recent reports suggest the possibility of a transvenous approach for the interventional treatment of refractory angina and mitral valve regurgitation. In addition, the coronary venous system has been used as a route for the delivery of stem cells in patients with left ventricular dysfunction due to ischemic heart disease. We review the potential value of using a coronary venous approach in association with recent therapeutic developments in the interventional treatment of structural and ischemic heart disease. We will also discuss techniques related to coronary venous catheterization. (Circ Cardiovasc Intervent. 2008;1:134-142.)Key Words: catheterization Ⅲ catheters Ⅲ valves Ⅲ valvuloplasty Ⅲ veins M ore than a century ago, Pratt 1 first described the use of coronary veins to deliver arterial blood to ischemic myocardium. His experiments showed that the coronary veins could be used as conduits for oxygenated blood and could preserve myocardial viability in the absence of normal arterial perfusion. Early in the 20th century, Beck described a procedure to treat patients with severe angina. Coronary venous pressures were elevated by surgically narrowing the coronary sinus (CS) in association with a partial pericardectomy. [2][3][4] This procedure known as the Beck I procedure was later modified to include a vein graft from the descending aorta to the great cardiac vein and partial ligation of the CS. Thus, in the Beck II procedure, the coronary venous system was partially arterialized. Several patients reported relief from anginal symptoms. These elegant operations were performed many years before the first coronary artery bypass graft surgeries and without the aid of cardiopulmonary bypass equipment. However, with the introduction of coronary artery bypass surgery and because of the long-term complications resulting from permanent obstruction of venous drainage including CS thrombosis, late myocardial hemorrhage, venous engorgement, edema, and subsequent fibrosis, these techniques were abandoned in the mid-1970s.Because of the enormous progress in the treatment of ischemic heart disease in the second half of the 20th century, there is a growing population of patients with chronic heart disease, severely altered contractile function, refractory ischemia, and/or functional mitral regurgitation (MR) who are not good candidates for surgery.Recently, several techniques using coronary venous access have been developed for targeted delivery of pharmacological agents, mechanical devices, or stem cells.In this study, we review the anatomy of the coronary venous system and focus on its potential value for new therapeutic approaches in invasive cardiology. The use of the coronary venous system for routine electrophys...

show abstract

Beneficial Effects of Coronary Venous Retroinfusion of Superoxide Dismutase and Catalase on Reperfusion Arrhythmias, Myocardial Function, and Infarct Size in Dogs

Cited by 33 publications

References 0 publications

MDL 73,404: A Cardioselective Antioxidant that Protects Against Myocardial Reperfusion Injury

MDL 73,404: A Cardioselective Antioxidant that Protects Against Myocardial Reperfusion Injury

Selective retroinfusion of GSH and cariporide attenuates myocardial ischemia–reperfusion injury in a preclinical pig model

Trans-Coronary-Venous Interventions

Contact Info

Product

Resources

About